Treatment‐Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet‐Rich Plasma in Bladder Pain Syndrome

Documenti analoghi

• Correction to “Treatment‐Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet‐Rich Plasma in Bladder Pain Syndrome”
  Pubblicazione: (2026)
• Selective Bladder Denervation via Radiofrequency Ablation Versus Intravesical Onabotulinum Toxin A for Refractory Overactive Bladder: The Short‐Term Results of A Preliminary Randomized Controlled Trial
  di: Salih Zeki Sönmez, et al.
  Pubblicazione: (2025)
• Definition Change and Update of Clinical Guidelines for Interstitial Cystitis and Bladder Pain Syndrome
  di: Yukio Homma, et al.
  Pubblicazione: (2024)
• Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co‐Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder
  di: Noritoshi Sekido, et al.
  Pubblicazione: (2025)
• Transient Receptor Potential Melastatin 8 Contributes to Cystitis‐Induced Neuronal Sprouting and Pain Hypersensitivity Through AKT/mTOR Signaling Pathway in Interstitial Cystitis/Bladder Pain Syndrome
  di: Liyang Wu, et al.
  Pubblicazione: (2024)